enzyme technologies - download.e-bookshelf.de · evolution to develop new industrial biocatalysts...
Post on 24-Oct-2019
0 Views
Preview:
TRANSCRIPT
ENZYME TECHNOLOGIES
CHEMICAL BIOLOGY OF ENZYMES FORBIOTECHNOLOGY AND PHARMACEUTICAL
APPLICATIONS
(A Series Consisting of Three Volumes)
Volume I. Enzyme Technologies: Metagenomics, Evolution, Biocatalysis, andBiosynthesisEditors: Wu-Kuang Yeh, Hsiu-Chiung Yang, and James R. McCarthy
Volume II. Enzyme Technologies in Drug DiscoveryEditors: Hsiu-Chiung Yang, Wu-Kuang Yeh, and James R. McCarthy
Volume III. Design of Enzyme Inhibitors for TherapeuticsEditors: James R. McCarthy, Hsiu-Chiung Yang, and Wu-Kuang Yeh
ENZYME TECHNOLOGIES
Metagenomics, Evolution, Biocatalysis,and Biosynthesis
Edited by
WU-KUANG YEHPreClinOmics, Inc., Indianapolis, Indiana
HSIU-CHIUNG YANGEli Lilly and Company, Indianapolis, Indiana
JAMES R. MCCARTHYIndiana University–Purdue University, Indianapolis, Indiana
A JOHN WILEY & SONS, INC., PUBLICATION
Copyright 2010 by John Wiley & Sons, Inc. All rights reserved.
Published by John Wiley & Sons, Inc., Hoboken, New Jersey.Published simultaneously in Canada.
No part of this publication may be reproduced, stored in a retrieval system, or transmitted in anyform or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise,except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, withouteither the prior written permission of the Publisher, or authorization through payment of theappropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers,MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requeststo the Publisher for permission should be addressed to the Permissions Department, John Wiley &Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online athttp://www.wiley.com/go/permission.
Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their bestefforts in preparing this book, they make no representations or warranties with respect to theaccuracy or completeness of the contents of this book and specifically disclaim any impliedwarranties of merchantability or fitness for a particular purpose. No warranty may be created orextended by sales representatives or written sales materials. The advice and strategies containedherein may not be suitable for your situation. You should consult with a professional whereappropriate. Neither the publisher nor author shall be liable for any loss of profit or any othercommercial damages, including but not limited to special, incidental, consequential, or otherdamages.
For general information on our other products and services or for technical support, please contactour Customer Care Department within the United States at (800) 762-2974, outside the UnitedStates at (317) 572-3993 or fax (317) 572-4002.
Wiley also publishes its books in a variety of electronic formats. Some content that appears in printmay not be available in electronic formats. For more information about Wiley products, visit ourweb site at www.wiley.com.
Library of Congress Cataloging-in-Publication Data:
Enzyme technologies: metagenomics, evolution, biocatalysis, and biosynthesis / edited by Wu-Kuang Yeh, Hsiu-Chiung Yang and James R. McCarthy.
p. cm.Includes index.Summary: Enzyme Technologies: Metagenomics, Evolution, Biocatalysis, and Biosynthesis
highlights how, what, and where enzymes have become critical in biotechnology andpharmaceutical applications. This book provides in-depth reviews of metagenomics, naturalbiodiversity, directed enzyme and pathway evolution, as well as enzyme optimization in thediscovery of novel enzymes and natural products. The book also discusses biocatalysis principleand applications in “green chemistry” for developing and producing active pharmaceuticalingredients with significant economical and environmental benefits. In addition, this volume dealswith applications involving combinatorial biosynthesis and pathway and enzyme engineering toproduce novel bioactive compounds, as well as to improve yields of natural and modified products.– Provided by publisher.
ISBN 978-0-470-28624-1 (hardback)1. Enzymes–Biotechnology. 2. Pharmaceutical biotechnology. I. Yeh, Wu-Kuang, 1942–
II. Yang, Hsiu-Chiung. III. McCarthy, James R., 1943–TP248.65.E59E59144 2010660.6′34–dc22
2010022384Printed in the United States of America
10 9 8 7 6 5 4 3 2 1
CONTENTS
Contributors vii
Preface ix
PART A NEW APPROACHES TO FINDING ANDMODIFYING ENZYMES 1
1 Functional Metagenomics as a Technique for the Discovery ofNovel Enzymes and Natural Products 3Luke A. Moe, Matthew D. McMahon, and Michael G. Thomas
2 Directed Enzyme and Pathway Evolution 41Jacob Vick and Claudia Schmidt-Dannert
3 Combining Natural Biodiversity and Molecular-DirectedEvolution to Develop New Industrial Biocatalysts and Drugs 77Laurent Fourage, Celine Ayrinhac, Johann Brot, Christophe Ullmann,Denis Wahler, and Jean-Marie Sonet
4 Principles of Enzyme Optimization for the Rapid Creation ofIndustrial Biocatalysts 99Richard J. Fox and Lori Giver
v
vi CONTENTS
PART B BIOCATALYTIC APPLICATIONS 125
5 Enzyme Catalysis in the Synthesis of Active PharmaceuticalIngredients 127Animesh Goswami
6 Enzymatic Processes for the Production of PharmaceuticalIntermediates 185David Rozzell and Jim Lalonde
7 Novel Developments Employing Redox Enzymes: OldEnzymes in New Clothes 199Kurt Faber, Silvia M. Glueck, Birgit Seisser, and Wolfgang Kroutil
PART C BIOSYNTHETIC APPLICATIONS 251
8 Drug Discovery and Development by CombinatorialBiosynthesis 253Matthew A. DeSieno, Carl A. Denard, and Huimin Zhao
9 Reprogramming Daptomycin and A54145 Biosynthesis toProduce Novel Lipopeptide Antibiotics 285Richard H. Baltz, Kien T. Nguyen, and Dylan C. Alexander
10 Pathway and Enzyme Engineering and Applications forGlycodiversification 309Lishan Zhao and Hung-wen Liu
Index 363
CONTRIBUTORS
Dylan C. Alexander, Cubist Pharmaceuticals, Inc., Lexington, Massachusetts
Celine Ayrinhac, Proteus, Nımes, France
Richard H. Baltz, Cubist Pharmaceuticals, Inc., Lexington, Massachusetts
Johann Brot, Proteus, Nımes, France
Carl A. Denard, Department of Chemical and Biomolecular Engineering andInstitute for Genomic Biology, University of Illinois at Urbana-Champaign,Urbana, Illinois
Matthew A. DeSieno, Department of Chemical and Biomolecular Engineer-ing and Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois
Kurt Faber, Department of Chemistry, Organic and Bioorganic Chemistry, Uni-versity of Graz, Graz, Austria
Laurent Fourage, Proteus, Nımes, France
Richard J. Fox, Codexis, Inc., Redwood City, California
Lori Giver, Codexis, Inc., Redwood City, California
Silvia M. Glueck, Department of Chemistry, Organic and Bioorganic Chemistry,University of Graz, Graz, Austria
vii
viii CONTRIBUTORS
Animesh Goswami, Process Research and Development, Bristol-Myers Squibb,New Brunswick, New Jersey
Wolfgang Kroutil, Department of Chemistry, Organic and Bioorganic Chemistry,University of Graz, Graz, Austria
Jim Lalonde, Codexis, Inc., Redwood City, California
Hung-wen Liu, Division of Medicinal Chemistry, College of Pharmacy, andDepartment of Chemistry and Biochemistry, University of Texas at Austin,Austin, Texas
Matthew D. McMahon, Department of Bacteriology, University of Wisconsin–Madison, Madison, Wisconsin
Luke A. Moe, Department of Plant and Soil Sciences, University of Kentucky,Lexington, Kentucky
Kien T. Nguyen, Cubist Pharmaceuticals, Inc., Lexington, Massachusctts
David Rozzell, Sustainable Chemistry Solutions, Burbank, California
Claudia Schmidt-Dannert, Department of Biochemistry, Molecular Biology andBiophysics, University of Minnesota, St. Paul, Minnesota
Birgit Seisser, Department of Chemistry, Organic and Bioorganic Chemistry,University of Graz, Graz, Austria
Jean-Marie Sonet, PCAS Biosolution, Longjumeau, France
Michael G. Thomas, Department of Bacteriology, University of Wisconsin–Madison, Madison, Wisconsin
Christophe Ullmann, Proteus, Nımes, France
Jacob Vick, Department of Biochemistry, Molecular Biology and Biophysics,University of Minnesota, St. Paul, Minnesota
Denis Wahler, Proteus, Nımes, France
Huimin Zhao, Department of Chemical and Biomolecular Engineering and Insti-tute for Genomic Biology, and Departments of Chemistry, Biochemistry, andBioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois
Lishan Zhao, Amyris Biotechnologies, Emeryville, California
PREFACE
The continuous improvement of human health and quality of life can be linkeddirectly to the discovery, development, manufacture, and applications of pharma-ceutical agents. Although many drugs for various human diseases are available,there are still numerous unmet medical needs, providing plenty of opportunitiesto researchers in the pharmaceutical and biotechnology industries. Drug discov-ery is a high-risk and potentially high-reward endeavor, costing approximately$1 billion in recent years for a new drug to reach the marketplace. Enzymes andtheir multiple applications play a critical role, both in vitro and in vivo, in thediscovery and development process for most new therapeutic agents. To assistresearchers in taking advantage of practical enzyme tools and strategies, one ofthe current editors coordinated the publication of a previous enzyme-based drugdiscovery book: Enzyme Technologies for Pharmaceutical and BiotechnologicalApplications (HA Kirst, WK Yeh, and MJ Zmjewski, eds., Marcel Dekker, NewYork, 2001). With respect to the field of enzymes for drug discovery, there havebeen significant and exciting advances in the first decade of the twenty-first cen-tury, and the current editors are pleased to produce the first in a series of threevolumes on Chemical Biology of Enzymes for Biotechnology and PharmaceuticalApplications.
The three editors have a combined pharmaceutical discovery experience ofover 60 years. Through several years of a highly collaborative effort, the edi-tors anticipate providing the three unique enzyme-focused books soon: Volume I,Enzyme Technologies: Metagenomics, Evolution, Biocatalysis, and Biosynthesis ;Volume II, Enzyme Technologies in Drug Discovery ; and Volume III, Design ofEnzyme Inhibitors for Therapeutics . The book chapters in each Enzyme Technolo-gies volume, contributed by highly experienced biotechnology and pharmaceuti-cal scientists, present many key enzyme areas that are critical for drug discovery,
ix
x PREFACE
development, and production. Thus, for all potential and practicing researchers,from beginners to experts, the three enzyme-based volumes are unique and infor-mative for both training and improving enzyme skills and strategies for drugdiscovery, development, and manufacture.
The first volume consists of three parts: A, New Approaches to Finding andModifying Enzymes; B, Biocatalytic Applications; and C, Biosynthetic Applica-tions. In Part A, Moe, McMahon, and Thomas describe functional metagenomicsas a technique for the discovery of novel enzymes and natural products inChapter 1. The chapter focuses on the emerging field of metagenomics and appli-cations for identification of novel enzymes and natural products from a full DNAcontent of soil-dwelling microbes. Next, in Chapter 2, Vick and Schmidt-Dannertdescribe directed enzyme and pathway evolution. The authors present the prac-tical applications of directed evolution to enzymes and pathways, discuss thetolerance of enzymes for multiple mutations and the potential benefits of neutraldrift and “adaptive evolution” and describe in vitro evolution of one or moremetabolic functions in assembled pathways, allowing the synthesis of new iso-prenoid or acetate-derived natural products. In Chapter 3, Fourage, Sonet, andcolleagues discuss combining natural biodiversity and molecular-directed evo-lution to develop new industrial biocatalysts and drugs. The authors exploreapproaches to the discovery and design of biocatalysts based on the combineduse of biodiversity screening and molecular-directed evolution, and the impactof these approaches in drug development. Part A is completed with Chapter 4 byFox and Giver on the principles of enzyme optimization for the rapid creation ofindustrial biocatalysts. The authors discuss the critical interplay of three orthog-onal aspects for efficient enzyme optimization: the fitness function, diversitygeneration, and the search algorithm.
In Part B, biocatalytic applications can be considered “green chemistry” forvery significant economical and environmental benefits in developing and produc-ing key pharmaceutical ingredients. Chapter 5, by Goswami, on enzyme catalysisin the synthesis of active pharmaceutical ingredients, based on the high selectivityof enzymatic transformations, provides an extensive review of specific applica-tions of different reactions in producing active pharmaceutical ingredients andpotential benefits with associated issues. Chapter 6, by Rozzell and Lalonde,deals with enzymatic processes for the production of pharmaceutical interme-diates. Examples are given of ketoreductase-based methods for the productionof key precursors of two blockbuster drugs (atorvastatin, trade name Lipitor,Pfizer; and montelukast, trade name Singulair, Merck), providing higher stereo-chemical purity of the final product and dramatic reductions in solvent use andwaste. Chapter 7, by Faber, Glueck, Seisser, and Kroutil, covers novel devel-opments employing redox enzymes. The authors provide an overview of recentdevelopments employing enzymes in organic synthesis and focus on dehydroge-nases for the reduction of sterically demanding ketones. Also covered are clonedenoate reductases from the “old yellow enzyme family” as popular catalysts forasymmetric reduction of activated alkenes.
PREFACE xi
Part C deals with applications involving the modification of enzymes andpathways for producing novel pharmaceutical intermediates and products aswell as for improving yields of natural and modified products. Chapter 8, byDeSieno, Denard, and Zhao, provides an extensive overview of drug discoveryand development by combinatorial biosynthesis. The chapter highlights somepast accomplishments, exemplified by major efforts in polyketide synthases andnonribosomal peptide synthases, as well as recent advances in combinatorialbiosynthesis, including new tools for manipulating biosynthetic pathways andan expanding list of heterologous hosts for the production of improved drugs.Chapter 9, by Baltz, Nguyen, and Alexander describes the reprogramming ofdaptomycin and A54145 biosynthesis to produce novel lipopeptide antibiotics.The chapter is an extensive review on applying combinatorial biosynthesis amongmultiple compatible hosts for generating many new derivatives of daptomycinand A54145, and some that have improved properties relative to daptomycin andA54145. Chapter 10, the final chapter, by Zhao and Liu covers pathway andenzyme engineering and applications for glycodiversification. The authors reportthat numerous promiscuous sugar biosynthetic enzymes and their correspondingglycosyltransferases toward alternative substrates have facilitated efforts to cre-ate novel chemical entities with altered sugar structures via pathway and enzymeengineering and thus highlight the great potential of glycodiversification as aneffective strategy for development of new therapeutic agents in drug discovery.
The editors graciously acknowledge outstanding contributions by two scien-tific consultants to the first volume of the Enzyme Technologies series. HerbKirst and Milt Zmijewski, co-editors of the earlier Enzyme Technologies book,were extremely helpful in identifying and recommending the most appropriateenzyme topics and authors for inclusion in this volume. Also, Dr. Zmijewskiwas involved extensively in reviewing the entire manuscript. Without their sig-nificant assistance, the content of the volume would be much less satisfactoryand timely. The editors are thankful to all the authors for close and in somecases time-consuming collaboration in multiple reviews toward producing thehighest-quality chapter manuscripts possible with consistent formats. The edi-tors are pleased by the agreement, suggestions, and encouragement from thepublishers to produce a truly unique and potentially highly useful Enzyme Tech-nologies series to benefit current and future researchers for drug discovery anddevelopment.
WU-KUANG YEHPreClinOmics, Inc.HSIU-CHIUNG YANGEli Lilly and Company
JAMES R. MCCARTHYIndiana University–Purdue UniversityIndianapolis, Indiana
PART A
NEW APPROACHES TO FINDINGAND MODIFYING ENZYMES
1
1FUNCTIONAL METAGENOMICSAS A TECHNIQUE FOR THEDISCOVERY OF NOVEL ENZYMESAND NATURAL PRODUCTS
Luke A. MoeDepartment of Plant and Soil Sciences, University of Kentucky, Lexington, Kentucky
Matthew D. McMahon, and Michael G. ThomasDepartment of Bacteriology, University of Wisconsin–Madison, Madison, Wisconsin
I. INTRODUCTION
The industrial use of biocatalysts and the recent reemphasis on the isolationof natural products with desired biological activities are driving the search fornew mechanisms for accessing the metabolic potential of microorganisms. Thisemphasis on microorganisms comes from an appreciation of the enormous biodi-versity found within them [1–4] and the understanding that traditional culturingtechniques to isolate these organisms have only enabled us to access approx-imately 1% of the microbial population present in a soil environment [5–7].Further, it is reasonable to assume that this low level of culturability will befound in many other ecological niches. Due to this limited access to the fullmetabolic potential in a targeted environment, there is a clear interest in devel-oping techniques allowing us access to the metabolic potential of the remaining99% of microorganisms.
One approach that aims to circumvent the limitations of culturability is the useof metagenomics. The term metagenome was introduced to define the combined
Enzyme Technologies: Metagenomics, Evolution, Biocatalysis, and Biosynthesis,Edited by Wu-Kuang Yeh, Hsiu-Chiung Yang, and James R. McCarthyCopyright 2010 John Wiley & Sons, Inc.
3
4 NOVEL ENZYMES AND NATURAL PRODUCTS
FIGURE 1 Construction and functional screening of a metagenomic DNA library fromsoil. (See insert for color representation of the figure.)
genomes of all the organisms in a particular environment, with metagenomicsreferring to a collection of techniques allowing access to this genomic informa-tion [8]. The shared features of metagenomic techniques are that the total DNAof the microbial population is extracted from the environment and cloned intoappropriate bacterial cloning vectors in a culture-independent manner (Fig. 1);thus, this technique has the potential to access the 99% of the metabolic potentialthat has previously been inaccessible.
Once metagenomic DNA has been extracted from an environment ofinterest and the associated DNA library has been constructed, there are twomechanisms for analyzing the metabolic potential present. One approach is touse sequence-based methods whereby the library is sequenced and analyzedfor genes of interest. Although this approach has been successful in identifyingnew homologs of enzymes of interest (e.g., bacteriorhodopsin homologs [9])and in gaining an understanding of total microbial community present [10], itdoes have limitations regarding the identification of new and novel biocatalysts.Because sequence-based identification of enzymes relies on relatively highlevels of sequence identity, only those enzymes displaying significant homologyto enzymes known to catalyze a specific reaction will be recognized. Thus, thoseenzymes displaying low sequence identity to known functional classes, andnovel enzymes that exhibit the desired activity but show no homology to knownfunctional classes, will not be identified using sequence-based techniques alone.
Alternatively, functional metagenomics is based on detecting a desired bio-logical activity that has been introduced into the host organism by virtue of therecombinant metagenomic clone. Using this function-based approach, metage-nomic clones encoding a variety of desired activities have been discovered; these
CONSTRUCTION OF METAGENOMIC DNA LIBRARIES 5
activities include esterases [11,12] and nitrile hydratases [13], enzymes respon-sible for the production of natural products (e.g., antibiotics [11] and pigments[14]), and antibiotic resistance genes [15,16]. The power of this approach isderived from the ability to identify clones encoding the desired biological activityin a large metagenomic library (often more than 106 recombinant clones) withoutprior sequence knowledge and without requiring a large-scale sequencing project.
Although successful, this approach to metagenomic DNA analysis also hasits limitations. The most obvious limitation is the ability to devise a phenotypicscreen to identify clones of interest. The second limitation deals with the heterol-ogous host itself. Although Escherichia coli has proven to be an extraordinarilycompliant host, it is not always able to express genes and produce functionalproteins from distantly related microorganisms. This limitation can be due toE. coli lacking the necessary regulatory elements to turn on expression of thegene clusters or the failure of E. coli to recognize the gene promoters due toa lack of the appropriate sigma factors. Additional issues arise when screen-ing for the production of natural products, since E. coli may lack the necessarycofactors or precursors required for production of the metabolite. The promise offunctional metagenomics is emphasized in this chapter and we provide the readerwith information on the steps that various researchers have taken to circumventthe limitations discussed above.
The field of metagenomics has grown enormously recently and it is nearlyimpossible to adequately summarize all the advances in sequence-based and func-tional genomics. Instead, what we have chosen to do here is to provide the readerwith information on, and references for construction of, a metagenomic DNAlibrary from a specific environment (e.g., soils/sediments) and to provide optionsfor how such a library can be screened using functional genomics approaches.
In discussing the construction and functional screening of a soil metagenome,we have divided this chapter into several sections. First, we discuss briefly thechoice of source material, which can be important in enrichment for a desired bio-logical activity. Second, we provide details on how to isolate metagenomic DNAfrom soils/sediments and prepare it for cloning. Third, we discuss the construc-tion of a metagenomic DNA library. Fourth, we provide examples of functionalmetagenomic screens used for identifying clones with various biological activi-ties. Finally, we provide a brief summary and some thoughts on what challengeslay ahead for metagenomics.
II. CONSTRUCTION OF METAGENOMIC DNA LIBRARIES
A. Choice of Source Material
Our research has focused on functional metagenomics from soil-derived DNAlibraries. Our focus on this environment is driven by two factors. First, it is nowquite evident that the soil environment has enormous biological and metabolicdiversity. One gram of soil has between 4 × 107 and 2 × 109 prokaryotic cells[17,18]. Furthermore, Torsvik and colleagues have estimated that this vast numberof prokaryotic cells consists of 3000 to 11,000 different genomes [5,6]. This
6 NOVEL ENZYMES AND NATURAL PRODUCTS
estimate is likely to be an underestimate based on the likelihood that there willbe a number of rare and underrepresented members of this population. Thus,there is enormous metabolic potential from a single gram of soil.
Although we have focused on mesophilic soils/sediments, there are a numberof examples of other soil environments and other ecological niches that havebeen investigated. For soils/sediments these include extreme environments suchas high temperatures [19], high and low pH [20], and high salt [21], in addition tocultivated and uncultivated fields [11,15,22], and different types of soils (e.g., clay[23], sandy [24], loam [15]). There is also a trans-European project that focuseson metagenomic analysis of disease-suppressive soils to identify componentsproduced by soil inhabitants that can be exploited for agricultural purposes [25].
Although there has been a significant focus on soils/sediments, this has notbeen the only environment of focus. Other environments include such diverseareas as animal gastrointestinal tracts for the identity of β-glucanases [26], marinesponges to identify natural products [27], and the resident microbiota of the gypsymoth for resistance determinants [16]. In the end, the choice of starting materialcan influence the success of a functional metagenomic screen.
B. Isolating DNA from Soils and Sediments
There are two general methods by which DNA is obtained from soil samples:the direct lysis and cell separation (or cell extraction) methods. As their namesimply, they differ according to whether bacterial cells are separated from theenvironmental matrix prior to lysis. In the following section we provide overviewsof both methods, including advantages and disadvantages of each. However, forthe purposes of this chapter, we believe the reader may be more interested in thedirect lysis method, and we give a more extensive outline of a protocol in use inour labs. Although we do not offer a comprehensive review of methods for theisolation of DNA from environmental samples, we refer the reader to a numberof references that address these techniques in detail [28–33].
Direct Lysis Method The direct lysis method for obtaining DNA reportedlyresults in larger quantities of DNA isolated from samples [30] and thus a morerepresentative picture of the genetic material present in a sample. However,because lysis is done in the presence of the soil matrix, isolated DNA extractstypically include contaminants that may hinder downstream DNA manipulationsteps. Further, the harsh chemical and mechanical steps involved in processingsamples typically result in smaller DNA fragments available for cloning [29].Nevertheless, direct lysis is the more popular method of the two for researchersinterested in functional screening, due primarily to its relative simplicity (com-mercial kits are available for small-insert DNA library cloning), ease in sampleprocessing, limited time input, and demonstrated success in producing librariesfrom which enzymes of interest can be identified (Table 1). A number of papersdescribe individual steps meant to enhance the viability of the DNA during theprocessing steps; these papers are noted during the description of the protocol.
TA
BL
E1
Enz
ymat
icA
ctiv
itie
sId
enti
fied
Usi
ngF
unct
iona
lM
egag
enom
ics
Enz
yme
Cla
ssV
ecto
rA
mou
ntof
Posi
tive
Clo
nes
and
Enz
yme
Scre
enin
gM
etho
d(A
vera
geIn
sert
Size
)D
NA
Scre
ened
aR
ecov
ered
Ref
.
Lip
ase/
este
rase
Lip
ase/
este
rase
Rec
ombi
nant
E.c
oli
met
agen
omic
libra
rypl
ated
onL
Bag
arsu
pple
men
ted
with
trib
utyr
in;
posi
tive
clon
esid
entifi
edby
pres
ence
ofcl
ear
halo
arou
ndco
lony
pEpi
FOS-
5(3
5kb
)N
R(e
stim
ate
1.2
Gb)
8[6
0]
Rec
ombi
nant
E.c
oli
met
agen
omic
libra
rypl
ated
onL
Bag
arsu
pple
men
ted
with
α-n
apht
hyl
acet
ate,
then
reac
ted
with
Fast
Blu
eR
Rto
dete
ctes
tera
seac
tivity
;re
actio
nw
ithα
-nap
htho
lre
sult
sin
form
atio
nof
adi
azo
dye
and
char
acte
rist
icco
lor
arou
ndco
lony
λZ
AP
(5.5
kb)
NR
(est
imat
e77
Mb)
11[2
0]
Rec
ombi
nant
E.c
oli
met
agen
omic
libra
rypl
ated
onL
Bag
arsu
pple
men
ted
with
3%B
acto
Lip
id;
posi
tive
clon
esid
entifi
edby
pres
ence
ofcl
ear
halo
arou
ndco
lony
pBel
oBA
C11
(27
kb)
∼100
Mb
2[1
1]
Pol
ysac
char
ide
hydr
olys
isC
ellu
lase
Rec
ombi
nant
E.c
oli
met
agen
omic
libra
rypl
ated
onL
Bag
ar,
plat
esth
enov
erla
idw
ithto
pag
arco
ntai
ning
0.1%
Ost
azin
Bri
llian
tR
edhy
drox
yeth
ylce
llulo
se;
posi
tive
clon
esid
entifi
edby
aye
llow
halo
arou
ndth
eco
lony
pBel
oBA
C11
(27
kb)
∼100
Mb
0[1
1]
(Con
tinu
edov
erle
af)
7
TA
BL
E1
(Con
tinue
d)
Enz
yme
Cla
ssV
ecto
rA
mou
ntof
Posi
tive
Clo
nes
and
Enz
yme
Scre
enin
gM
etho
d(A
vera
geIn
sert
Size
)D
NA
Scre
ened
aR
ecov
ered
Ref
.
Rec
ombi
nant
E.c
oli
met
agen
omic
libra
rypl
ated
onL
Bag
arsu
pple
men
ted
with
0.1%
carb
oxym
ethy
lcel
lulo
se;
afte
rgr
owth
for
7da
ysth
epl
ates
wer
eflo
oded
with
Con
goR
ed;
posi
tive
clon
esid
entifi
edby
acl
eari
ngzo
near
ound
the
colo
ny
pSup
erC
OS1
(NR
)N
R(e
stim
ate
2.8
Gb)
1[6
9]
Am
ylas
eR
ecom
bina
ntE
.col
im
etag
enom
iclib
rary
plat
edon
Bac
toSt
arch
agar
,pl
ates
wer
eflo
oded
with
Bac
to-s
tabi
lized
Gra
mio
dine
afte
r3
days
;po
sitiv
ecl
ones
iden
tified
byan
oran
geha
loar
ound
the
colo
ny
pBel
oBA
C11
(27
kb)
∼100
Mb
8[1
1]
Cel
lobi
ohyd
rola
seR
ecom
bina
ntE
.col
im
etag
enom
iclib
rary
plat
edon
LB
agar
supp
lem
ente
dw
ith4-
met
hylu
mbe
llife
ryl-β
-D-c
ello
bios
ide;
posi
tive
clon
esid
entifi
edby
the
fluor
esce
ntre
actio
npr
oduc
t
pWE
B-T
NC
(35.
1kb
)1.
14G
b0
[56]
β-G
luco
sida
seR
ecom
bina
ntE
.col
im
etag
enom
iclib
rary
plat
edw
ithes
culin
hydr
ate
(aβ
-glu
cosi
de)
and
ferr
icam
mon
ium
citr
ate;
posi
tive
clon
esid
entifi
edby
the
blac
kpr
ecip
itate
resu
lting
from
the
reac
tion
ofth
ehy
drol
ytic
prod
uct
ofes
culin
with
ferr
icio
n
pWE
B-T
NC
(35.
1kb
)1.
14G
b7
[56]
8
Chi
tina
seR
ecom
bina
ntE
.col
im
etag
enom
iclib
rary
grow
nw
ithflu
orog
enic
subs
trat
e4-
met
hylu
mbe
llife
ryl-β
-D-N
,N
′ -di
acet
ylch
itobi
osid
e;ac
tivity
scor
edby
pres
ence
offlu
ores
cent
hydr
olys
ispr
oduc
t
Rep
orte
das
“Epi
cent
reC
opyC
ontr
olfo
smid
libra
ryki
t,”pr
esum
ably
pCC
1FO
S(4
0kb
)
NR
(est
imat
e24
0M
b)4
[55]
Xyl
anas
eR
ecom
bina
ntE
.col
im
etag
enom
iclib
rary
plat
edan
dov
erla
idw
ithto
pag
arco
ntai
ning
0.1
–0.
3%az
ody
e-lin
ked
xyla
n;po
sitiv
ecl
ones
iden
tified
bydi
sapp
eara
nce
ofth
edy
eco
lor
NR
(3–
6kb
)∼1
Mb
4[7
0]
Rec
ombi
nant
E.c
oli
met
agen
omic
libra
rypl
ated
onL
Bag
arsu
pple
men
ted
with
1%R
emaz
olB
rilli
ant
Blu
exy
lan;
posi
tive
clon
esid
entifi
edby
acl
eari
ngzo
near
ound
the
colo
ny
pMB
M80
3(7
–10
kb)
NR
(est
imat
e20
4M
b)1
[57]
Oxy
gena
seP
olyp
heno
lox
idas
eR
ecom
bina
ntE
.col
im
etag
enom
iclib
rary
plat
edon
NZ
Yso
ftag
arsu
pple
men
ted
wit
h50
µM
syri
ngal
dazi
ne,
posi
tive
clon
esid
entifi
edby
the
pres
ence
ofa
purp
leha
losu
rrou
ndin
gth
eco
lony
λZ
AP
(5.5
kb)
NR
1[5
4]
Mon
ooxy
gena
seR
ecom
bina
ntE
.col
im
etag
enom
iclib
rary
plat
edon
LB
agar
;ap
pear
ance
ofbl
ueco
lor
indi
cate
sfo
rmat
ion
ofin
digo
from
indo
leby
hydr
oxyl
atio
nfo
llow
edby
spon
tane
ous
dim
eriz
atio
n
pZE
rO-2
(5.5
kb)
NR
(est
imat
e35
8M
b)1
[71]
(Con
tinu
edov
erle
af)
9
TA
BL
E1
(Con
tinue
d)
Enz
yme
Cla
ssV
ecto
rA
mou
ntof
Posi
tive
Clo
nes
and
Enz
yme
Scre
enin
gM
etho
d(A
vera
geIn
sert
Size
)D
NA
Scre
ened
aR
ecov
ered
Ref
.
Ext
radi
oldi
oxyg
enas
eR
ecom
bina
ntE
.col
im
etag
enom
icpC
C1F
OS
(33
kb)
3.2
Gb
91[5
9]cl
ones
grow
nin
LB
brot
h,th
enly
sed;
the
lysa
tew
ascl
arifi
edan
dca
tech
olw
asad
ded
to0.
5m
M;
posi
tive
clon
esid
entifi
edba
sed
onfo
rmat
ion
ofa
yello
wri
ng-c
leav
age
prod
uct
4-H
ydro
xyph
enyl
pyru
vate
Rec
ombi
nant
E.c
oli
met
agen
omic
pSup
erC
os1
(40
kb)
NR
(est
imat
e1.
2G
b)5
[72]
diox
ygen
ase
clon
esgr
own
inL
Bbr
oth
supp
lem
ente
dw
ith60
0µ
g/m
LL
-tyr
osin
e;po
sitiv
ecl
ones
iden
tified
asth
ose
that
prod
uce
abr
own
pigm
ent
Acy
lhom
oser
ine
lact
one
(AH
L)–
med
iate
dqu
orum
sens
ing
acti
vati
onan
din
hibi
tion
AH
Lsy
ntha
seM
etag
enom
icD
NA
clon
espC
C1F
OS
(39
kb),
653
Mb
12[4
4]tr
ansf
orm
edin
toan
E.c
oli
pCC
1BA
C(1
3–
47bi
osen
sor
stra
inen
gine
ered
tokb
),pS
uper
BA
Cse
nse
AH
Ls;
prod
ucti
onof
AH
Ls
(5–
33kb
)by
am
etag
enom
iccl
one
resu
ltsin
aG
FP-p
ositi
veph
enot
ype
for
the
colo
ny
10
Rec
ombi
nant
E.c
oli
met
agen
omic
clon
esas
saye
don
anag
arpl
ate
for
the
abil
ity
tore
stor
eA
HL
-dep
ende
ntpi
gmen
tpr
oduc
tion
toa
Chr
omob
acte
rium
stra
inth
atha
sha
dits
AH
Lsy
ntha
sekn
ocke
dou
t
NR
NR
0[7
3]
AH
Lla
cton
ase
Met
agen
omic
DN
Acl
ones
tran
sfor
med
into
anE
.col
ibi
osen
sor
stra
inen
gine
ered
tose
nse
AH
Ls;
the
reco
mbi
nant
clon
esth
engr
own
inth
epr
esen
ceof
anA
HL
know
nto
activ
ate
the
repo
rter
;po
sitiv
ecl
ones
iden
tified
asth
ose
clon
esth
atdi
dno
tflu
ores
ce
pCC
1FO
S(3
9kb
),pC
C1B
AC
(13
–47
kb),
pSup
erB
AC
(5–
33kb
)
653
Mb
2[4
4]
Rec
ombi
nant
E.c
oli
met
agen
omic
clon
esas
saye
don
anag
arpl
ate
for
the
abili
tyto
inte
rfer
ew
ithan
AH
L-s
ensi
ngC
hrom
obac
teri
umbi
osen
sor
stra
inin
the
pres
ence
ofA
HL
s
NR
NR
1[7
3]
Oth
erP
rote
ase
Rec
ombi
nant
E.c
oli
met
agen
omic
libra
rypl
ated
onL
Bag
arsu
pple
men
ted
with
1%(w
/v)
skim
milk
;po
sitiv
ecl
ones
iden
tified
byth
epr
esen
ceof
acl
ear
halo
surr
ound
ing
the
colo
ny
pCC
1FO
S(N
R)
NR
1[7
4]
(Con
tinu
edov
erle
af)
11
TA
BL
E1
(Con
tinue
d)
Enz
yme
Cla
ssV
ecto
rA
mou
ntof
Posi
tive
Clo
nes
and
Enz
yme
Scre
enin
gM
etho
d(A
vera
geIn
sert
Size
)D
NA
Scre
ened
aR
ecov
ered
Ref
.
Nit
rila
seR
ecom
bina
ntE
.col
im
etag
enom
iclib
rary
grow
nin
M9
med
ium
lack
ing
ani
trog
enso
urce
,su
pple
men
ted
with
ani
trile
subs
trat
e;gr
owth
ofre
com
bina
ntcl
ones
onth
ism
ediu
min
dica
ted
that
the
met
agen
omic
DN
Ain
sert
conf
erre
dth
eab
ility
tolib
erat
eam
mon
iafr
omth
eni
trile
subs
trat
eth
roug
ha
nitr
ilase
reac
tion,
allo
win
gth
ecl
one
tous
eam
mon
iaas
the
sole
nitr
ogen
sour
ce
λZ
AP
(1–
10kb
)N
R(b
etw
een
0.65
Gb
and
6.5
Tb)
>20
0[4
3]
Pho
spha
tase
Rec
ombi
nant
E.c
oli
met
agen
omic
libra
rypl
ated
onnu
trie
ntag
arsu
pple
men
ted
with
40µ
g/m
L5-
brom
o-4-
chlo
ro-3
-ind
olyl
phos
phat
e(X
-pho
spha
te);
posi
tive
clon
esid
entifi
edba
sed
onbl
ueco
lony
colo
r
pJO
E93
0(3
.2kb
)N
R(e
stim
ate
102
Mb)
13[5
3]
Men
adio
nere
sist
ance
Rec
ombi
nant
E.c
oli
met
agen
omic
clon
escu
lture
din
LB
brot
hsu
pple
men
ted
with
aco
ncen
trat
ion
ofm
enad
ione
toxi
cto
the
host
stra
in(0
.6m
M);
posi
tive
clon
esid
entifi
edas
thos
eth
atgr
ew
pCC
1FO
S(3
3kb
)N
R(e
stim
ate
3.2
Gb)
4[6
1]
12
β-L
acta
mas
eR
ecom
bina
ntE
.col
im
etag
enom
iclib
rary
plat
edon
LB
agar
supp
lem
ente
dw
itha
conc
entr
atio
nof
β-l
acta
man
tibi
otic
toxi
cto
the
host
cell
(con
cent
ratio
nva
ries
depe
ndin
gon
the
β-l
acta
m);
posi
tive
clon
esid
entifi
edas
thos
eth
atgr
ew
pCF4
30(5
–10
kb),
pCC
1FO
S(3
0kb
),pC
C1B
AC
(8kb
)
12.4
Gb
13[1
6]
5-E
noyl
pyru
vyls
hiki
mat
e-3-
phos
phat
esy
ntha
se(E
PSP
S)
Met
agen
omic
DN
Acl
ones
assa
yed
inan
E.c
oli
stra
inde
ficie
ntin
EPS
PSac
tivity
for
the
abili
tyto
reco
ver
grow
th;
beca
use
EPS
PSis
the
targ
etfo
rth
ehe
rbic
ide
glyp
hosa
te;
scre
enin
gto
okpl
ace
atva
ryin
gco
ncen
trat
ions
ofgl
ypho
sate
tose
lect
for
glyp
hosa
te-r
esis
tant
enzy
mes
,al
low
ing
grow
thof
the
host
stra
in
pAC
YC
(2–
6kb
)N
R(e
stim
ate
1M
b)3
[62]
Ben
zoyl
form
ate
deca
rbox
ylas
e(B
FD
)M
etag
enom
icD
NA
clon
estr
ansf
orm
edin
toa
BFD
-defi
cien
tst
rain
ofP
seud
omon
aspu
tida
;po
sitiv
ecl
ones
iden
tified
asth
ose
that
conf
erre
dth
eab
ility
togr
owon
benz
oylf
orm
ate
asth
eso
leca
rbon
sour
ce
pBB
R1M
CS
(2–
10kb
)N
R(e
stim
ate
∼100
Mb)
1[5
1]
(Con
tinu
edov
erle
af)
13
TA
BL
E1
(Con
tinue
d)
Enz
yme
Cla
ssV
ecto
rA
mou
ntof
Posi
tive
Clo
nes
and
Enz
yme
Scre
enin
gM
etho
d(A
vera
geIn
sert
Size
)D
NA
Scre
ened
aR
ecov
ered
Ref
.
Gly
cero
lde
hydr
atas
eM
etag
enom
icD
NA
clon
estr
ansf
orm
edin
toan
E.c
oli
stra
inen
gine
ered
toco
ntai
nal
lth
ege
nes
requ
ired
for
anae
robi
cgr
owth
ongl
ycer
olas
aso
leca
rbon
sour
cew
ithth
eex
cept
ion
ofgl
ycer
olde
hydr
atas
e;po
sitiv
ecl
ones
iden
tified
asth
ose
that
conf
erre
dth
eab
ilit
yto
grow
unde
rth
ese
cond
itio
ns
pBlu
escr
ipt
SK(+
)(3
.3kb
,5
kb,
3.4
kb)
NR
(est
imat
e1.
3G
b)2
[63]
Alc
ohol
dehy
drog
enas
eR
ecom
bina
ntE
.col
ior
Rhi
zobi
umle
gum
inos
arum
plat
edon
min
imal
med
iaw
ith0.
1%(v
/v)
etha
nol
asth
eso
leca
rbon
sour
ce;
posi
tive
clon
esid
entifi
edas
thos
eth
atco
nfer
red
the
abili
tyto
grow
unde
rth
ese
cond
itio
ns
pLA
FR3
(25
kb)
2.75
Gb
1[3
7]
Am
idas
eM
etag
enom
iccl
ones
sele
cted
inan
E.c
oli
leuc
ine
auxo
trop
hfo
rth
eab
ility
tore
cove
rgr
owth
onm
ediu
mco
ntai
ning
vari
ous
amid
e-lin
ked
leuc
ine
deri
vativ
es;
posi
tive
clon
esid
entifi
edas
thos
eth
atgr
ewun
der
thes
eco
nditi
ons
pZE
rO-2
(5.2
kb)
NR
6[4
2]
14
D-3
-hyd
roxy
buty
rate
dehy
drog
enas
eR
ecom
bina
ntSi
norh
izob
ium
mel
ilot
ian
dE
.col
ist
rain
sw
ere
sele
cted
for
the
abil
ity
tous
eD
-3-h
ydro
xybu
tyra
teas
aso
leca
rbon
sour
ce;
posi
tive
clon
esid
entifi
edas
thos
eth
atgr
ewun
der
thes
eco
ndit
ions
pRK
7813
(33
kb)
1.5
Gb
34[3
8]
DN
Ase
Rec
ombi
nant
E.c
oli
met
agen
omic
clon
esw
ere
plat
edon
Bac
toD
NA
sem
ethy
lgr
een
agar
;po
sitiv
ecl
ones
iden
tified
byan
oran
geha
losu
rrou
ndin
gth
eco
lony
pBel
oBA
C11
(27
kb)
∼100
Mb
1[1
1]
aIf
NR
(not
repo
rted
),es
timat
esw
ere
mad
eby
mul
tiply
ing
the
num
ber
ofcl
ones
scre
ened
byth
eav
erag
em
etag
enom
icD
NA
inse
rtsi
zew
hen
thes
efig
ures
wer
ere
port
ed.
15
16 NOVEL ENZYMES AND NATURAL PRODUCTS
The protocol described below has been used in our laboratories to obtainDNA sufficient for small- and large-insert libraries; it was developed by LynnWilliamson (University of Wisconsin–Madison, Department of Bacteriology),drawing from collaborative research and experimentation with a number of pub-lished protocols.
1. Sieve soil through a fine (ca. 2 mm, sterile) mesh to eliminate roots andparticulates.
2. Split 100 g of the sieved soil into two 50-g samples, and add each sampleto a sterile 250-mL centrifuge bottle. To each bottle add 75 mL of Zbuffer [at pH 8.0: 100 mM Tris-HCl; 100 mM sodium phosphate; 100 mMethylenediaminetetraacetic acid (EDTA); 1.5M NaCl; 1% w/v cetrimoniumbromide (CTAB)].
3. Lyse the soil samples using two freeze–thaw cycles; freezing must becomplete and can be accomplished using liquid nitrogen or a dry ice/ethanolbath. The samples can be thawed by incubation in a 65◦C water bath.Freezing in a dry ice bath will take about 40 min; complete thawing willtake about the same amount of time.
4. To the final thaw at 65◦C, add 9 mL of 20% sodium dodecyl sulfate and4.5 mL of 5 M guanidinium isothiocyanate. Mix by gentle inversion.
5. Incubate at 65◦C for 2 h with occasional mixing.6. Centrifuge at 10◦C, 20 min at 15,000 × g.7. Pipette off the supernatant, containing DNA, into two clean, sterile 250-mL
centrifuge bottles. Be sure to use wide-bore pipette tips when handling theDNA in this step, and in the remaining steps, to avoid shearing.
8. To the DNA-containing solution, add 25 mL of chloloform/isoamyl alcohol(24 : 1) and mix gently for 10 min at room temperature.
9. Centrifuge at 10◦C, 20 min at 15,000 × g.10. Pipette off the supernatant, containing DNA, into two clean, sterile 250-mL
centrifuge bottles.11. Precipitate DNA by adding isopropanol to 70% (about 40 mL per bottle)
and mixing gently for 5 min. Let this sample incubate without mixing atroom temperature for an additional 20 min.
12. Centrifuge at 10◦C, 40 min at 15,000 × g.13. A visible brownish pellet should form—this is the DNA. Carefully pour
off the supernatant, and remove all of the remaining liquid from the bottle.14. Resuspend the DNA pellet gently in a minimal amount of T10E10 (at pH 8.0:
10 mM Tris-HCl; 10 mM EDTA) using wide-bore pipette tips. 1 to 2 mLof T10E10 per tube should suffice. Using wide-bore pipette tips, aliquot theresuspended DNA solution equally into four 1.5-mL Eppendorf tubes.
15. Extract the DNA with an equal volume of Tris-buffered phenol/chloroform(commercially available, pH 8.0), invert to mix, and centrifuge at16,000 × g for 10 min at room temperature.
top related